Catecholamine storage vesicles and the metabolic syndrome: The role of the chromogranin A fragment pancreastatin

Diabetes, Obesity and Metabolism

Volumn 8, Issue 6, 2006, Pages 621-633

  Zhang, Kuixing ^a   Rao, Fangwen ^a   Wen, Gen ^a   Salem, Rany M ^a   Vaingankar, Sucheta ^a   Mahata, Manjula ^a   Mahapatra, Nitish R ^a   Lillie, Elizabeth O ^a   Cadman, Peter E ^a   Friese, Ryan S ^a   Hamilton, Bruce A ^a   Hook, Vivian Y ^a   Mahata, Sushil K ^a   Taupenot, Laurent ^a,b   O'Connor, Daniel T ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Catecholamine; Chromagranin; Free fatty acid; Glucose; Hypertension; Insulin

Indexed keywords

AMINO ACID DERIVATIVE; CARBOHYDRATE; CATECHOLAMINE; CELL PROTEIN; CHROMOGRANIN A; CHROMOGRANIN B; FATTY ACID; GLUCOSE; GLYCINE; HORMONE PRECURSOR; LIPID; NEUROTRANSMITTER RECEPTOR; PANCREASTATIN; PEPTIDE FRAGMENT; SECRETOGRANIN II; SERINE;

ADRENERGIC SYSTEM; AMINO ACID METABOLISM; AUTOCRINE EFFECT; CARBOHYDRATE METABOLISM; CARBOXY TERMINAL SEQUENCE; CATECHOLAMINE RELEASE; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; FATTY ACID METABOLISM; GENE LOCUS; GENETIC CODE; GENETIC VARIABILITY; GLUCOSE TRANSPORT; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; IN VIVO STUDY; LIPID METABOLISM; METABOLIC SYNDROME X; NERVE CELL; NEUROSECRETORY CELL; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TRANSPORT; QUALITATIVE ANALYSIS; REVIEW; SECRETORY GRANULE; STORAGE DISEASE;

EID: 33749464322     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00575.x     Document Type: Review

References (94)

1. Winkler H, Westhead E. The molecular organization of adrenal chromaffin granules. Neuroscience 1980; 5 (11): 1803-1823.
2. Winkler H. The composition of adrenal chromaffin granules: An assessment of controversial results. Neuroscience 1976; 1 (2): 65-80.
3. Parmer RJ, O'Connor DT. Enkephalins in human phaeochromocytomas: localization in immunoreactive, high molecular weight form to the soluble core of chromaffin granules. J Hypertens 1988; 6 (3): 187-198.
4. Videen JS, Mezger MS, Chang YM, O'Connor DT. Calcium and catecholamine interactions with adrenal chromogranins. Comparison of driving forces in binding and aggregation. J Biol Chem 1992; 267 (5): 3066-3073.
5. O'Connor DT, Burton D, Deftos LJ. Chromogranin A: Immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands. Life Sci 1983; 33 (17): 1657-1663.
6. O'Connor DT, Frigon RP. Chromogranin A, the major catecholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J Biol Chem 1984; 259 (5): 3237-3247.
7. O'Connor DT, Klein RL, Thureson-Klein AK, Barbosa JA. Chromogranin A: localization and stoichiometry in large dense core catecholamine storage vesicles from sympathetic nerve. Brain Res 1991; 567 (2): 188-196.
8. Banks P, Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 1965; 97 (3): 40C-41C.
9. Helle KB. Some chemical and physical properties of the soluble protein fraction of bovine adrenal chromaffin granules. Mol Pharmacol 1966; 2 (4): 298-310.
10. Lee RW, Huttner WB. Tyrosine-O-sulfated proteins of PC12 pheochromocytoma cells and their sulfation by a tyrosylprotein sulfotransferase. J Biol Chem 1983; 258 (18): 11326-11334.
11. Rosa P, Zanini A. Characterization of adenohypophysial polypeptides by two-dimensional gel electrophoresis. II. Sulfated and glycosylated polypeptides. Mol Cell Endocrinol 1981; 24 (2): 181-193.
12. Fischer-Colbrie R, Laslop A, Kirchmair R. Secretogranin II: Molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Prog Neurobiol 1995; 46 (1): 49-70.
13. Huttner WB, Gerdes HH, Rosa P. The granin (chromogranin/secretogranin) family. Trends Biochem Sci 1991; 16 (1): 27-30.
14. Ottiger HP, Battenberg EF, Tsou AP, Bloom FE, Sutcliffe JG. 1B1075: A brain- and pituitary-specific mRNA that encodes a novel chromogranin/ secretogranin-like component of intracellular vesicles. J Neurosci 1990; 10 (9): 3135-3147.
15. Krisch K, Buxbaum P, Horvat G et al. Monoclonal antibody HISL-19 as an immunocytochemical probe for neuroendocrine differentiation. Its application in diagnostic pathology. Am J Pathol 1986; 123 (1): 100-108.
16. Mbikay M, Seidah NG, Chretien M. Neuroendocrine secretory protein 7B2: structure, expression and functions. Biochem J 2001; 357 (Pt 2): 329-342.
17. Ischia R, Lovisetti-Scamihorn P, Hogue-Angeletti R, Wolkersdorfer M, Winkler H, Fischer-Colbrie R. Molecular cloning and characterization of NESP55, a novel chromogranin-like precursor of a peptide with 5-HT1B receptor antagonist activity. J Biol Chem 1997; 272 (17): 11657-11662.
18. Taupenot L, Harper KL, O'Connor DT. Role of H+-ATPase-mediated acidification in sorting and release of the regulated secretory protein chromogranin A: Evidence for a vesiculogenic function. J Biol Chem 2005; 280 (5): 3885-3897.
19. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348 (12): 1134-1149.
20. Winkler H, Fischer-Colbrie R. The chromogranins A and B: The first 25 years and future perspectives. Neuroscience 1992; 49 (3): 497-528.
21. Mahapatra NR, O'Connor DT, Vaingankar SM et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 2005; 115 (7): 1942-1952.
22. Helle KB. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: Comparative and functional aspects. Biol Rev Camb Philos Soc 2004; 79 (4): 769-794.
23. Mahata SK, Kozak CA, Szpirer J et al. Dispersion of chromogranin/ secretogranin secretory protein family loci in mammalian genomes. Genomics 1996; 33 (1): 135-139.
24. Reiffen FU, Gratzl M. Chromogranins, widespread in endocrine and nervous tissue, bind Ca2+. FEBS Lett 1986; 195 (1-2): 327-330.
25. Grimes M, Iacangelo A, Eiden LE, Godfrey B, Herbert E. Chromogranin A: the primary structure deduced from cDNA clones reveals the presence of pairs of basic amino acids. Ann N Y Acad Sci 1987; 493: 351-378.
26. Konecki DS, Benedum UM, Gerdes HH, Huttner WB. The primary structure of human chromogranin A and pancreastatin. J Biol Chem 1987; 262 (35): 17026-17030.
27. Gorr SU, Shioi J, Cohn DV. Interaction of calcium with porcine adrenal chromogranin A (secretory protein-I) and chromogranin B (secretogranin I). Am J Physiol 1989; 257 (2 Pt 1): E247-E254.
28. Gerdes HH, Rosa P, Phillips E et al. The primary structure of human secretogranin II, a widespread tyrosine-sulfated secretory granule protein that exhibits low pH- and calcium-induced aggregation. J Biol Chem 1989; 264 (20): 12009-12015.
29. Yoo SH, Albanesi JP. High capacity, low affinity Ca2+ binding of chromogranin A. Relationship between the pH-induced conformational change and Ca2+ binding property. J Biol Chem 1991; 266 (12): 7740-7745.
30. Kelly RB. Pathways of protein secretion in eukaryotes. Science 1985; 230 (4721): 25-32.
31. Halban PA, Irminger JC. Sorting and processing of secretory proteins. Biochem J 1994; 299 (1): 1-18.
32. Arvan P, Castle D. Sorting and storage during secretory granule biogenesis: Looking backward and looking forward. Biochem J 1998; 332 (3): 593-610.
33. Yoo SH. pH-dependent binding of chromogranin B and secretory vesicle matrix proteins to the vesicle membrane. Biochim Biophys Acta 1993; 1179 (3): 239-246.
34. Chanat E, Huttner WB. Milieu-induced, selective aggregation of regulated secretory proteins in the trans-Golgi network. J Cell Biol 1991; 115 (6): 1505-1519.
35. Cool DR, Normant E, Shen F et al. Carboxypeptidase E is a regulated secretory pathway sorting receptor: Genetic obliteration leads to endocrine disorders in Cpe (fat) mice. Cell 1997; 88 (1): 73-83.
36. Thiele C, Gerdes HH, Huttner WB. Protein secretion: Puzzling receptors. Curr Biol 1997; 7 (8): R496-R500.
37. Thiele C, Huttner WB. Protein and lipid sorting from the trans-Golgi network to secretory granules-recent developments. Semin Cell Dev Biol 1998; 9 (5): 511-516.
38. Tooze SA, Martens GJ, Huttner WB. Secretory granule biogenesis: Rafting to the SNARE. Trends Cell Biol 2001; 11 (3): 116-122.
39. Taupenot L, Harper KL, Mahapatra NR, Parmer RJ, Mahata SK, O'Connor DT. Identification of a novel sorting determinant for the regulated pathway in the secretory protein chromogranin A. J Cell Sci 2002; 115 (Pt 24): 4827-4841.
40. Rozansky DJ, Wu H, Tang K, Parmer RJ, O'Connor DT. Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element. J Clin Invest 1994; 94 (6): 2357-2368.
41. Chanat E, Weiss U, Huttner WB, Tooze SA. Reduction of the disulfide bond of chromogranin B (secretogranin I) in the trans-Golgi network causes its missorting to the constitutive secretory pathways. EMBO J 1993; 12 (5): 2159-2168.
42. Chanat E, Weiss U, Huttner WB. The disulfide bond in chromogranin B, which is essential for its sorting to secretory granules, is not required for its aggregation in the trans-Golgi network. FEBS Lett 1994; 351 (2): 225-230.
43. Kromer A, Glombik MM, Huttner WB, Gerdes HH. Essential role of the disulfide-bonded loop of chromogranin B for sorting to secretory granules is revealed by expression of a deletion mutant in the absence of endogenous granin synthesis. J Cell Biol 1998; 140 (6): 1331-1346.
44. Glombik MM, Kromer A, Salm T, Huttner WB, Gerdes HH. The disulfide-bonded loop of chromogranin B mediates membrane binding and directs sorting from the trans-Golgi network to secretory granules. EMBO J 1999; 18 (4): 1059-1070.
45. Takiyyuddin MA, Cervenka JH, Sullivan PA et al. Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation 1990; 81 (1): 185-195.
46. Winkler H, Apps DK, Fischer-Colbrie R. The molecular function of adrenal chromaffin granules: Established facts and unresolved topics. Neuroscience 1986; 18 (2): 261-290.
47. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986; 324 (6096): 476-478.
48. Cadman PE, Rao F, Mahata SK, O'Connor DT. Studies of the dysglycemic peptide, pancreastatin, using a human forearm model. Ann N Y Acad Sci 2002; 971: 528-529.
49. Strub JM, Goumon Y, Lugardon K et al. Antibacterial activity of glycosylated and phosphorylated chromogranin A-derived peptide 173-194 from bovine adrenal medullary chromaffin granules. J Biol Chem 1996; 271 (45): 28533-28540.
50. Aardal S, Helle KB, Elsayed S, Reed RK, Serck-Hanssen G. Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 1993; 5 (4): 405-412.
51. Mahata SK, O'Connor DT, Mahata M et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997; 100 (6): 1623-1633.
52. Mahata SK, Mahata M, Wu H, Parmer RJ, O'Connor DT. Neurotrophin activation of catecholamine storage vesicle protein gene expression: signaling to chromogranin a biosynthesis. Neuroscience 1999; 88 (2): 405-424.
53. Mahata SK, Mahata M, Wen G et al. The catecholamine release-inhibitory 'catestatin'fragment of chromogranin a: Naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. Mol Pharmacol 2004; 66 (5): 1180-1191.
54. Kruger PG, Mahata SK, Helle KB. Catestatin (CgA344-364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides. Regul Pept 2003; 114 (1): 29-35.
55. Briolat J, Wu SD, Mahata SK et al. New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. Cell Mol Life Sci 2005; 62 (3): 377-385.
56. Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an 'on/off'switch controlling dense-core secretory granule biogenesis. Cell 2001; 106 (4): 499-509.
57. Kim T, Loh YP. Chromogranin A: A surprising link between granule biogenesis and hypertension. J Clin Invest 2005; 115 (7): 1711-1713.
58. Takiyyuddin MA, Parmer RJ, Kailasam MT et al. Chromogranin A in human hypertension. Influence of heredity. Hypertension 1995; 26 (1): 213-220.
59. O'Connor DT, Takiyyuddin MA, Printz MP et al. Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press 1999; 8 (5-6): 285-295.
60. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 2002; 20 (7): 1335-1345.
61. Wen G, Mahata SK, Cadman P et al. Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet 2004; 74 (2): 197-207.
62. Iacangelo AL, Fischer-Colbrie R, Koller KJ, Brownstein MJ, Eiden LE. The sequence of porcine chromogranin A messenger RNA demonstrates chromogranin A can serve as the precursor for the biologically active hormone, pancreastatin. Endocrinology 1988; 122 (5): 2339-2341.
63. Sanchez-Margalet V, Lucas M, Goberna R. Pancreastatin: Further evidence for its consideration as a regulatory peptide. J Mol Endocrinol 1996; 16 (1): 1-8.
64. Sanchez-Margalet V, Gonzalez-Yanes C, Santos-Alvarez J, Najib S. Pancreastatin. Biological effects and mechanisms of action. Adv Exp Med Biol 2000; 482: 247-262.
65. Gonzalez-Yanes C, Sanchez-Margalet V. Pancreastatin, a chromogranin A-derived peptide, inhibits leptin and enhances UCP-2 expression in isolated rat adipocytes. Cell Mol Life Sci 2003; 60 (12): 2749-2756.
66. Gonzalez-Yanes C, Sanchez-Margalet V. Pancreastatin, a chromogranin A-derived peptide, activates protein synthesis signaling cascade in rat adipocytes. Biochem Biophys Res Commun 2002; 299 (4): 525-531.
67. Kong C, Gill BM, Rahimpour R et al. Secretoneurin and chemoattractant receptor interactions. J Neuroimmunol 1998; 88 (1-2): 91-98.
68. Helle KB. Vasostatins. Vascular targets. Adv Exp Med Biol 2000; 482: 225-238.
69. Sanchez-Margalet V, Gonzalez-Yanes C, Najib S. Pancreastatin, a chromogranin A-derived peptide, inhibits DNA and protein synthesis by producing nitric oxide in HTC rat hepatoma cells. J Hepatol 2001; 35 (1): 80-85.
70. Gonzalez-Yanes C, Sanchez-Margalet V. Pancreastatin modulates insulin signaling in rat adipocytes: Mechanisms of cross-talk. Diabetes 2000; 49 (8): 1288-1294.
71. Sanchez-Margalet V, Calvo JR, Goberna R. Glucogenolytic and hyperglycaemic effect of 33-49 C-terminal fragment of pancreastatin in the rat in vivo. Horm Metab Res 1992; 24 (10): 455-457.
72. Sanchez-Margalet V, Calvo JR, Lucas M, Goberna R. Pancreastatin and its 33-49 C-terminal fragment inhibit glucagon-stimulated insulin in vivo. Gen Pharmacol 1992; 23 (4): 637-638.
73. Sanchez-Margalet V, Goberna R. Pancreastatin inhibits insulin-stimulated glycogen synthesis but not glycolysis in rat hepatocytes. Regul Pept 1994; 51 (3): 215-220.
74. Diaz-Troya S, Najib S, Sanchez-Margalet V. eNOS, nNOS, cGMP and protein kinase G mediate the inhibitory effect of pancreastatin, a chromogranin A-derived peptide, on growth and proliferation of hepatoma cells. Regul Pept 2005; 125 (1-3): 41-46.
75. Miyasaka K, Funakoshi A, Kitani K, Tamamura H, Fujii N, Funakoshi S. The importance of the C-terminal amide structure of rat pancreastatin to inhibit pancreatic exocrine secretion. FEBS Lett 1990; 263 (2): 279-280.
76. Zhang JX, Fasciotto BH, Darling DS, Cohn DV. Pancreastatin, a chromogranin A-derived peptide, inhibits transcription of the parathyroid hormone and chromogranin A genes and decreases the stability of the respective messenger ribonucleic acids in parathyroid cells in culture. Endocrinology 1994; 134 (3): 1310-1316.
77. Fasciotto BH, Trauss CA, Greeley GH, Cohn DV. Parastatin (porcine chromogranin A347-419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion. Endocrinology 1993; 133 (2): 461-466.
78. Wu HJ, Rozansky DJ, Parmer RJ, Gill BM, O'Connor DT. Structure and function of the chromogranin A gene. Clues to evolution and tissue-specific expression. J Biol Chem 1991; 266 (20): 13130-13134.
79. O'Connor DT, Cadman PE, Smiley C et al. Pancreastatin: Multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab 2005; 90 (9): 5414-5425.
80. Sanchez-Margalet V, Valle M, Lobon JA et al. Increased plasma pancreastatin-like immunoreactivity levels in non-obese patients with essential hypertension. J Hypertens 1995; 13 (2): 251-258.
81. Sanchez-Margalet V, Gonzalez-Yanes C, Santos-Alvarez J, Najib S. Characterization of pancreastatin receptor and signaling in rat HTC hepatoma cells. Eur J Pharmacol 2000; 397 (2-3): 229-235.
82. Sanchez-Margalet V, Santos-Alvarez J, Diaz-Troya S. Purification of pancreastatin receptor from rat liver membranes. Methods Mol Biol 2003; 228: 187-194.
83. Sanchez-Margalet V, Gonzalez-Yanes C. Pancreastatin inhibits insulin action in rat adipocytes. Am J Physiol 1998; 275 (6 Pt 1): E1055-E1060.
84. Sanchez-Margalet V, Lobon JA, Gonzalez A, Fernandez-Soto ML, Escobar-Jimenez F, Goberna R. Increased plasma pancreastatin-like levels in gestational diabetes: Correlation with catecholamine levels. Diabetes Care 1998; 21 (11): 1951-1954.
85. Funakoshi A, Tateishi K, Shinozaki H, Matsumoto M, Wakasugi H. Elevated plasma levels of pancreastatin (PST) in patients with non-insulin-dependent diabetes mellitus (NIDDM). Regul Pept 1990; 30 (2): 159-164.
86. Eskeland NL, Zhou A, Dinh TQ et al. Chromogranin A processing and secretion: Specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. J Clin Invest 1996; 98 (1): 148-156.
87. Prigge ST, Mains RE, Eipper BA, Amzel LM. New insights into copper monooxygenases and peptide amidation: Structure, mechanism and function. Cell Mol Life Sci 2000; 57 (8-9): 1236-1259.
88. Yasothornsrikul S, Greenbaum D, Medzihradszky KF et al. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc Natl Acad Sci USA 2003; 100 (16): 9590-9595.
89. Benyon RJ, Bond JS. Proteolytic enzymes: A practical approach. 1st edition. IRL Press at Oxford University: Oxford, 1989.
90. Schmidt WE, Siegel EG, Kratzin H, Creutzfeldt W. Isolation and primary structure of tumor-derived peptides related to human pancreastatin and chromogranin A. Proc Natl Acad Sci USA 1988; 85 (21): 8231-8235.
91. Funakoshi S, Tamamura H, Ohta M et al. Isolation and characterization of a tumor-derived human pancreastatin-related protein. Biochem Biophys Res Commun 1989; 164 (1): 141-148.
92. Nakano I, Funakoshi A, Miyasaka K et al. Isolation and characterization of bovine pancreastatin. Regul Pept 1989; 25 (2): 207-213.
93. Zhang T, Mochizuki T, Kogire M et al. Pancreastatin: Characterization of biological activity. Biochem Biophys Res Commun 1990; 173 (3): 1157-1160.
94. Funakoshi A, Miyasaka K, Kitani K, Tamamura H, Funakoshi S, Yajima H. Bioactivity of synthetic C-terminal fragment of rat pancreastatin on endocrine pancreas. Biochem Biophys Res Commun 1989; 158 (3): 844-849.